90 related articles for article (PubMed ID: 17895469)
21. Screening for pancreatic cancer.
Poruk KE; Firpo MA; Mulvihill SJ
Adv Surg; 2014; 48():115-36. PubMed ID: 25293611
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
[TBL] [Abstract][Full Text] [Related]
23. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
Maluf-Filho F; Kumar A; Gerhardt R; Kubrusly M; Sakai P; Hondo F; Matuguma SE; Artifon E; Monteiro da Cunha JE; César Machado MC; Ishioka S; Forero E
J Clin Gastroenterol; 2007; 41(10):906-10. PubMed ID: 18090159
[TBL] [Abstract][Full Text] [Related]
24. RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells.
Ali S; Ahmad A; Aboukameel A; Bao B; Padhye S; Philip PA; Sarkar FH
Cancer Lett; 2012 Jun; 319(2):173-181. PubMed ID: 22261338
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of K-Ras plasma membrane localization.
Cho KJ; van der Hoeven D; Hancock JF
Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
[TBL] [Abstract][Full Text] [Related]
26. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
[TBL] [Abstract][Full Text] [Related]
27. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
28. Current and future intratumoral targeted treatment for pancreatic cancer.
Zarogoulidis P; Pavlioglou P; Pivert PL; Machairiotis N; Katsikogiannis N; Kougioumtzi I; Tsimogiannis K; Kakolyris S; Courcoutsakis N; Tsiouda T; Sakkas A; Makrantonaki D; Zarogoulidis K
Ther Deliv; 2014 Aug; 5(8):913-26. PubMed ID: 25337648
[TBL] [Abstract][Full Text] [Related]
29. Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer.
Marchese R; Muleti A; Brozzetti S; Gandini O; Brunetti E; French D
Br J Cancer; 2004 Jun; 90(11):2243. PubMed ID: 15150585
[No Abstract] [Full Text] [Related]
30. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
31. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer.
Sorenson GD
Clin Cancer Res; 2000 Jun; 6(6):2129-37. PubMed ID: 10873061
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog/Ras interactions regulate early stages of pancreatic cancer.
Pasca di Magliano M; Sekine S; Ermilov A; Ferris J; Dlugosz AA; Hebrok M
Genes Dev; 2006 Nov; 20(22):3161-73. PubMed ID: 17114586
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
[TBL] [Abstract][Full Text] [Related]
34. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
[TBL] [Abstract][Full Text] [Related]
35. [Development of basic research of pancreatic cancer: from genetically-engineered mouse models to bedside].
Ijichi H
Nihon Shokakibyo Gakkai Zasshi; 2014 Aug; 111(8):1561-9. PubMed ID: 25100345
[No Abstract] [Full Text] [Related]
36. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
37. [Immunohistological study on ras and myc oncogene products in pancreatic cancer].
Motoshima K; Kohara N; Shiogama T; Fujii M; Nakago S; Tsunoda T; Nagata Y
Nihon Geka Gakkai Zasshi; 1990 Jan; 91(1):123-9. PubMed ID: 2138243
[TBL] [Abstract][Full Text] [Related]
38. Possibilities for future collaborative research on small renal masses (SRM's).
Beatty JD; Patel A
Arch Ital Urol Androl; 2009 Jun; 81(2):113-7. PubMed ID: 19760867
[TBL] [Abstract][Full Text] [Related]
39. Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy.
Hingorani SR
Cancer Cell; 2015 Aug; 28(2):151-3. PubMed ID: 26267532
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of children after esophagogastroduodenoscopy for chronic abdominal pain.
Bourke B
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):409. PubMed ID: 25130939
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
